The FDA has approved Vimpat (lacosamide, from UCB) as an adjunct treatment for adults with partial-onset seizures. In three clinical trials involving 1,300 patients, Vimpat-treated patients reduced their number of seizures by half, reduced their seizure frequency, and improved their seizure freedom rates as compared to placebo.

Vimpat will be designated a controlled substance and is expected to be available in early 2009 in tablet and IV infusion formulations.

For more information call (866) 822-0068 or visit www.ucb-group.com.